Unity Biotechnology CEO Anirvan Ghosh, Ph.D. (Unity) Nearly a year after dropping its lead program and sinking its stock, Unity Biotechnology appears to be coming back on track with positive data in its phase 1 study in patients with advanced vascular eye disease. The anti-aging biotech said Tuesday its small-molecule inhibitor of Bcl-xL, a senolytic therapeutic, was well tolerated in patients with diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD). Unity shares were up about 9% in early trading Tuesday morning. The study of UBX1325 was conducted in patients for whom anti–vascular endothelial growth factor (anti-VEGF) therapy was not considered to be beneficial anymore. Anti-VEGF treatments include Roche's Lucentis, Regeneron's Eylea, Novartis' Beovu and Roche's Avastin.